Literature DB >> 1378079

Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination.

D Valmori1, A Pessi, E Bianchi, G Corradin.   

Abstract

Synthetic constructs were assembled as multiple Ag peptide systems containing repetitive sequences of Plasmodium falciparum and Plasmodium berghei, the causative agents of human and murine malaria respectively, and two universal human tetanus toxin T cell epitopes 830-843 and 947-967. These constructs were tested for antibody production in mice and for their capacity to stimulate human PBL and tetanus toxin-specific T cell clones. A high antibody titer can be obtained in mice when multiple Ag peptide systems are injected in various adjuvants or in PBS alone. Furthermore, all constructs can activate PBL from every donor tested. However, a variable response was obtained when different clones specific for the two tetanus toxin universal epitopes were used. These constructs may represent possible candidates for a malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378079

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Roberto Petracca; Aldo Giannozzi; Francesco Norelli; Rino Rappuoli; Guido Grandi; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

2.  NLRP3 inflammasome is a target for development of broad-spectrum anti-infective drugs.

Authors:  James D Thacker; Brian J Balin; Denah M Appelt; Sihem Sassi-Gaha; Mitali Purohit; Richard F Rest; Carol M Artlett
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 3.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

4.  Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.

Authors:  Karin Baraldo; Elena Mori; Antonella Bartoloni; Francesco Norelli; Guido Grandi; Rino Rappuoli; Oretta Finco; Giuseppe Del Giudice
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

Authors:  C Yang; W E Collins; J S Sullivan; D C Kaslow; L Xiao; A A Lal
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 6.  The development of a multivalent DNA vaccine for malaria.

Authors:  R C Hedstrom; D L Doolan; R Wang; M J Gardner; A Kumar; M Sedegah; R A Gramzinski; J B Sacci; Y Charoenvit; W R Weiss; M Margalith; J A Norman; P Hobart; S L Hoffman
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Daniel Feldman; Fen Yu; Kemp B Cease
Journal:  Vaccine       Date:  2014-11-30       Impact factor: 3.641

8.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

9.  Presentation of T-cell epitopes assembled as multiple-antigen peptides to murine and human T lymphocytes.

Authors:  D Grillot; D Valmori; P H Lambert; G Corradin; G Del Giudice
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

Review 10.  The optimization of helper T lymphocyte (HTL) function in vaccine development.

Authors:  J Alexander; J Fikes; S Hoffman; E Franke; J Sacci; E Appella; F V Chisari; L G Guidotti; R W Chesnut; B Livingston; A Sette
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.